Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis.
Our flexible CuTraceTM platform combines copper radiometals with a variety of highly specific cancer-targeting molecules to rapidly develop novel therapeutic and diagnostic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for hospitals and patients. Nuclidium’s differentiated “diagnostic to therapeutic” approach de-risks our development pathway. With innovation as our core, we overcome supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities.
We are a diverse and interdisciplinary team focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients.
Company Details
- Employees
- 20
- Founded
- -
- Address
- Bäumleingasse, Basel,bs 4051,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- swissnuclides.ch
- Keywords
- Tracer Development, Diagnostic Imaging, Therapeutic Imaging, Molecular Imaging, Hybrid Imaging, R&D, Radionuclide Production, Precision Oncology, Targeted Radiotherapy.
- HQ
- Basel, BS
Nuclidium Ag Questions
Nuclidium Ag's website is swissnuclides.ch
Nuclidium Ag's LinkedIn profile is https://ch.linkedin.com/company/nuclidium
Nuclidium Ag has
20 employees.
View email and phone details for 20
employees at Nuclidium Ag.
Nuclidium Ag's industry is
Biotechnology Research
Nuclidium Ag's top competitors are
Linathera,
Comphya,
Renasant Bio,
Actithera,
Radiopharm Theranostics,
Artbio,
Evlabio,
Angelini Ventures,
Neva Sgr,
Askearth.
Nuclidium Ag's categories are Biotechnology Research
Nuclidium Ag's founding year is 2017
